The expression and significance of FOXO3a and Jab1 in human ovarian cancer

Open access


Background: Ovarian carcinoma represents one of the most insidious and aggressive cancers. Ovarian carcinoma is the most lethal gynecological malignancy. To discover new relevant biomarkers to increase specificity and sensitivity for early diagnosis and prognosis of ovarian cancer is important and urgently needed. FOXO3a possesses a large series function including cellular proliferation, transformation, differentiation, and longevity. Jab1 is also known as subunit 5 (CSN5) of the COP9 signalosome (CSN), a multifunctional protein complex involved in modulating signal transduction, gene transcription, and protein stability.

Objective: To investigate the importance of FOXO3a and Jab1 in ovarian cancer.

Method: Immunohistochemical analysis was performed on formalin-fixed paraffin sections of 46 specimens. Statistical analysis was conducted using the Stat View 5.0 software package.

Result: We found that Foxo3a expression correlates significantly with FIGO disease stage (p < 0.05) and lymph node involvement. Jab1 expression correlates significantly with disease stage and lymph node involvement (p < 0.05). A multivariate Cox proportional hazard model showed that Foxo3a and Jab1 were the strongest independent predictors of survival (p < 0.05), the second predictor being FIGO disease stage and lymph node involvement.

Conclusion: Understanding the precise role of Jab1 and Foxo3a in ovarian cancer progression will not only increase our knowledge of the biology of ovarian cancer but may also enable development of an novel therapeutic strategy via suppression of Jab1.

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351:2519-29.

2. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001; 127:73-9.

3. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007; 120:2479-87.

4. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96:857-68.

5. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol. 2002; 156:817-28.

6. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004; 380:297-309.

7. Claret F-X, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996; 383:453-7.

8. Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2001; 2:96-101.

9. Schwechheimer C, Deng XW. COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol. 2001; 11:420-6.

10. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, et al. Jab1 expression is associated with inverse expression of p27kip1 and poor prognosis in epithelial ovarian tumors. Clin Cancer Res. 2001; 7:4130-5.

11. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret F-X. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27Kip1. Cancer Res. 2003; 63:2977-81.

12. Rassidakis GZ, Claret F-X, Lai R, Zhang Q, Sarris AH, McDonnell TJ, et al. Expression of p27Kip1 and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9:1121-8.

13. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27KIP1 and poor prognosis in oral squamous cell carcinomas. Oncology. 2003; 65: 355-62.

14. Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T, et al. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer. 2006; 107:154-61.

15. Doerfler W, Hohlweg U, M ller K, Remus R, Heller H, Hertz J. Foreign DNA integration-perturbations of the genome-oncogenesis. Ann N Y Acad Sci. 2001; 945:276-88.

16. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007; 120:2479-87.

17. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a Forkheaddependent pathway. Science. 2004; 306:2105-8.

18. Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res. 2008; 10:R21. doi:

19. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005; 102:1649-54.

20. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. Cell. IêB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. 2004; 117: 225-37.

Journal Information

IMPACT FACTOR 2017: 0.209
5-year IMPACT FACTOR: 0.243

CiteScore 2017: 0.24

SCImago Journal Rank (SJR) 2017: 0.162
Source Normalized Impact per Paper (SNIP) 2017: 0.173


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 81 81 6
PDF Downloads 31 31 1